Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Daniel Morgensztern
Publikováno v:
Journal of Thoracic Disease. 11:S1963-S1965
Immunotherapy with monoclonal antibodies against programmed death-1 (PD-1) or its ligand (PD-L1) were approved for previously treated advanced non-small cell lung cancer (NSCLC) based on the results from four randomized trials showing improved surviv
With the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) recurrence, gefitinib is the first targeted drug to be approved for advanced non-small cell lung cancer (NSCLC) that failed to respond to chemotherapy (1). A great quant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb48909348edb0f0130a794ad0ad27fe
https://europepmc.org/articles/PMC6384356/
https://europepmc.org/articles/PMC6384356/
Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC 'capitulate'?
Autor:
Balazs Halmos, Brian Ko
The mesenchymal-epithelial transition factor (MET)/hepatocyte growth factor (HGF) axis is a key pathway in acquired resistance against epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in EGFR-mutated non-small cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9622b55f6acb421e90c355b810770c28
https://europepmc.org/articles/PMC6328688/
https://europepmc.org/articles/PMC6328688/
Autor:
Justin F. Gainor
Publikováno v:
Translational Lung Cancer Research. 5:343-346
Discovered in lung cancer in 2007, anaplastic lymphoma kinase ( ALK ) rearrangements have emerged as important therapeutic targets in non-small cell lung cancer ( NSCLC ) (1). Like epidermal growth factor receptor (EGFR) mutations, ALK rearrangements
Autor:
Jianliang Yang, Gai Wenlin, Weijing Zhang, Liangzhi Xie, Peng Liu, Yuanyuan Song, Shuxiang Zhang, Xiaohong Han, Xiaohui He, Yuankai Shi, Jiarui Yao, Lin Gui, Yan Qin
Publikováno v:
Chinese Journal of Cancer Research
Objective: This study was designed to determine the safety, pharmacokinetics and biologic effects of a human-mouse chimeric anti-CD20 monoclonal antibody (SCT400) in Chinese patients with CD20-positive B-cell non-Hodgkin's lymphoma (CD20+ B-cell NHL)
Autor:
Andreas Tiefenbacher, Robert Pirker
The epidermal growth factor receptor (EGFR) has been established as a clinically relevant target for the treatment of patients with advanced non-small cell lung cancer (NSCLC) (1). EGFR blockade can be achieved by either monoclonal antibodies directe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c677368575f01b6294249441b3bf7207
https://europepmc.org/articles/PMC5720983/
https://europepmc.org/articles/PMC5720983/
We report a first case of a patient experiencing reactivation of pulmonary tuberculosis (TB) during treatment of oral tyrosine kinase inhibitor (TKI) with non-small cell lung cancer (NSCLC). A 44-year-old male patient visited the hospital with cough.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97dd3077f2cf23b1e2b99b675ad46ae5
https://europepmc.org/articles/PMC5594125/
https://europepmc.org/articles/PMC5594125/
Autor:
Sergio Amaro, Laura Llull
Natalizumab is a humanized monoclonal antibody against alpha-4 integrin (CD49d) that reduces the incursion of circulating leukocytes into the central nervous system across the endothelium (1).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad8ec539c0bb87a1c7b0839cc9f0690a
https://europepmc.org/articles/PMC5104619/
https://europepmc.org/articles/PMC5104619/
Autor:
Gianpiero Fasola, Giovanna De Maglio, Alessandro Follador, Maria Giulia Cangi, Lorenzo Gerratana, C. Lisanti, F. Cortiula, Salvatore Bonura
Publikováno v:
Annals of Translational Medicine. 7:14-14
We reported the case of a male patient suffering from a metastatic squamous cell carcinoma, harboring a complex inframe deletion in exon 19 of epidermal growth factor receptor (EGFR), treated with erlotinib and osimertinib and subsequently with immun
Publikováno v:
Annals of Blood. 3:49-49
Background: Prevention and management of thrombotic disorders is achieved through the use of anticoagulant drugs, including heparins, vitamin K antagonists (VKAs; namely warfarin) and the more recently developed antithrombotic agents [i.e., direct or